AB2 Bio

AB2 Bio is a clinical-stage biotechnology company developing targeted therapies for severe inflammatory diseases, with a core focus on IL-18-driven conditions like Hemophagocytic Lymphohistiocytosis (HLH) and Adult-Onset Still's Disease (AOSD). Its lead candidate, Tadekinig alfa, a recombinant human IL-18 binding protein, has demonstrated a strong safety profile in early trials and is now in a pivotal Phase 3 study for primary HLH. The company recently secured a significant U.S. option and licensing agreement with Nippon Shinyaku, validating its approach and providing a potential path to commercialization. AB2 Bio operates as a private, pre-revenue entity leveraging its academic roots at EPFL to address niche, high-severity autoimmune disorders.

Targeted inhibition of the interleukin-18 (IL-18) pathway using a recombinant human IL-18 binding protein (Tadekinig alfa) to neutralize excess pro-inflammatory cytokine activity.

In the niche space of IL-18 targeted therapy, AB2 Bio appears to be a leader with its advanced clinical program. For HLH, competition includes chemotherapies, immunosuppressants, and bone marrow transplant, but no directly targeted biologic competitors are approved. In AOSD, it would compete with broader anti-cytokine therapies (e.g., IL-1, IL-6 inhibitors) and JAK inhibitors, offering a potentially differentiated mechanism.